Table 2 Subgroup analysis of progression-free survival (PFS)
Subgroup | Number of patients n (%) | Median PFS, months (95%CI) |
|---|---|---|
All patients | 40 (100%) | 6.0 (3.8–8.2) |
Liver metastasis | Â | Â |
 Yes | 9 (22.5%) | 7.1 (3.8–10.3) |
 No | 31 (77.5%) | 5.8 (3.1–8.4) |
Lung metastasis | Â | Â |
 Yes | 9 (22.5%) | 5.3 (3.0-7.6) |
 No | 31 (77.5%) | 7.1 (5.0-9.2) |
Bone metastasis | Â | Â |
 Yes | 13 (32.5%) | 7.4 (3.9–10.9) |
 No | 27 (67.5%) | 5.7 (4.2–7.2) |
Prior taxane therapy | Â | Â |
 Yes | 24 (60.0%) | 7.1 (5.0-9.1) |
 No | 16 (40.0%) | 4.5 (0.8–8.1) |
Prior anthracycline therapy | Â | Â |
 Yes | 32 (80.0%) | 7.5 (4.3–10.7) |
 No | 8 (20.0%) | 6.0 (3.3–8.7) |
Prior platinum therapy | Â | Â |
 Yes | 20 (50.0%) | 8.1 (5.2–11.0) |
 No | 20 (50.0%) | 5.0 (3.8–6.2) |